Guggenheim downgraded Seelos Therapeutics to Neutral from Buy without a price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SEEL:
- Seelos Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Seelos Therapeutics price target lowered to $1 from $4 at Benchmark
- Seelos (NASDAQ: SEEL) Tumbles as Phase 2 Trial Disappoints
- Seelos Therapeutics announces data from Phase II study of SLS-002
- Seelos Therapeutics files to sell 5M shares of common stock for holders